Mini-bioreactors for DOE screening

01Overview and value chain

Markers: [EC: FDA Process Validation Stage 1 & ICH Q8 Design Space | OECD: Industrial biotech | Regulator: FDA (USA), EMA (EU), NMPA (China)]

Mini-bioreactors for Design-of-Experiments (DOE) screening are the high-throughput on-ramp to bioprocess development: small (1-250 mL) parallel bioreactors that run 24 to 48 cultures simultaneously under individually controlled pH, dissolved oxygen and feed conditions, replacing the slow shake-flask era. The dominant platform is Sartorius’s ambr, a disposable 24- or 48-vessel automated system that delivers comparable performance to benchtop bioreactors at roughly 1/100th the volume and a tenth of the time, so a cell-line or clone screen that once took months now closes in days. m2p-labs’ BioLector adds shaken microtiter-plate screening with online OD, pH, DO and fluorescence monitoring, and Eppendorf’s DASbox provides four to 24 fully controlled 60 mL benchtop mini-bioreactors. Together these tools let developers map the ICH Q8 Design Space — the multidimensional envelope of acceptable process parameters — early, feeding scale-up models that satisfy FDA Stage 1 process validation. The market is concentrated in a handful of European platforms that have become standard equipment in every major biopharma and industrial-biotech process-development group.

The key directions of mini-bioreactors and DOE screening are:

1. Automated parallel mini-bioreactors (Automated Parallel Mini-Bioreactors): 24-48 disposable vessels with integrated liquid handling for automated inoculation, feeding and sampling — Sartorius ambr 15/250, the cell-culture and microbial workhorses.
2. Online-monitored micro-bioreactor plates (Online-Monitored Micro-Plates): shaken microtiter plates with online biomass, pH, DO and fluorescence readouts for high-density microbial strain screening — m2p-labs BioLector.
3. Benchtop controlled mini-bioreactors (Benchtop Mini-Bioreactors): four to 24 individually controlled 60 mL vessels giving true bioreactor control at small scale — Eppendorf DASbox, Applikon MiniBio.
4. DOE design-space mapping (DOE Design-Space Mapping): statistically designed experiment matrices that, run across these platforms, define the ICH Q8 Design Space and de-risk scale-up to pilot and GMP scale.

Sectoral value chain

[DOE design] ──> [parallel mini-bioreactor run] ──> [online analytics + sampling] ──> [data model]
                                             │
                                  (ICH Q8 Design Space)
                                             │
                                             ▼
[scale-up] <─── [lead-clone / condition selection] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Disposable mini-vessel formats (Disposable Mini-Vessels): single-use stirred or bubbled 10-250 mL vessels that eliminate cleaning and cross-contamination between DOE runs.
• Integrated liquid handling (Integrated Liquid Handling): onboard robotics for inoculation, feed addition and automated sampling into HPLC/at-line analytics (Hamilton, Tecan integration).
• Scale-down modelling (Scale-Down Modelling): matching mini-bioreactor mixing, kLa and power-input to pilot scale so DOE results transfer reliably.

02US

The United States is the largest market for mini-bioreactor DOE platforms — every major biopharma and CDMO process-development group runs ambr and DASbox fleets — and supplies the automation and analytics integrated around them.

automation integration, process-validation driver, CDMO fleets

• Hamilton Company: the Reno-based automation and sensor maker provides the precision liquid handling, sensors and integrated robotics that many mini-bioreactor DOE workflows pipe into for sampling and feed delivery.
• Process-validation driver: FDA Process Validation Stage 1 (process design) and ICH Q8 Design-Space expectations push US biopharma to characterise the design space early with parallel mini-bioreactor DOE.
• CDMO fleets: US CDMOs operate dense fleets of ambr and DASbox systems to run client clone screens and process characterisation at throughput.

03CN

China’s biopharma and industrial-biotech process-development groups have adopted the leading mini-bioreactor DOE platforms rapidly, while domestic bioreactor makers serve the broader upstream market.

platform adoption, strain-development demand, domestic makers

• Platform adoption: Chinese biologics and CDMO groups (WuXi, Innovent, Legend) run ambr, DASbox and BioLector fleets for cell-line and strain screening, aligned with NMPA process-validation expectations.
• Strain-development demand: China’s industrial-biotech and synthetic-biology build-out drives strong demand for microbial DOE screening (BioLector, DASGIP) for strain engineering.
• Domestic makers: local bioreactor manufacturers serve the conventional upstream market; the high-throughput DOE-platform segment remains led by the European platforms.

04EU

Europe authors the mini-bioreactor DOE category: three of the four leading platforms are German, with the fourth from the Netherlands.

ambr (Sartorius), BioLector (m2p-labs), DASbox (Eppendorf)

• Sartorius (Germany): the ambr 15 and ambr 250 automated mini-bioreactor systems run 24-48 disposable vessels with integrated liquid handling, the reference platform for cell-line and upstream-process DOE in cell-culture and microbial applications.
• m2p-labs (Germany): the BioLector platform screens shaken microtiter plates with online OD, pH, DO and fluorescence monitoring, optimised for high-throughput microbial strain and media screening.
• Eppendorf (Germany): the DASbox mini-bioreactor system provides four or 24 fully controlled 60 mL vessels, with the DASGIP parallel-bioreactor line for the next scale step.
• Applikon Biotechnology (Netherlands, Getinge): the MiniBio benchtop mini-bioreactor and my-Control controller add a flexible individually-controlled parallel option.

05Leading companies and research institutes

06Tech stack and innovations

The mini-bioreactor DOE stack rests on parallel small-volume control, rich online analytics and statistical design, each generation widening how much of the design space a single week can cover.

1. Automated parallel mini-vessels (Automated Parallel Vessels):
   • 24-48 disposable 10-250 mL vessels are run in parallel under individual pH, temperature and DO control with integrated robotic inoculation, feeding and sampling.
   • case: Sartorius ambr 250 delivers cell-culture performance comparable to benchtop reactors at ~100-1000x less volume per vessel.
2. Online microtiter monitoring (Online Microtiter Monitoring):
   • shaken microtiter plates are read non-invasively for biomass (OD), pH, DO and fluorescence, enabling hundreds of microbial conditions per run.
   • m2p-labs BioLector pairs this with microfluidic feeding (BioLector Pro) for fed-batch screening.
3. DOE design-space modelling (DOE Design-Space Modelling):
   • statistical design matrices (definitive screening, response-surface) are run across the platforms to map the ICH Q8 Design Space and rank clones/conditions.
   • multivariate models transfer setpoints to pilot and GMP scale via matched kLa and power-input scale-down.

07Value chains and production pipelines

Industrial pipeline of a DOE screening campaign (FDA Stage 1 / ICH Q8)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. DOE design             │ ───> │ 2. Parallel mini-bio run  │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Lead selection         │ <─── │ 3. Online analytics + model│
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Scale-down validation  │ ───> │ 6. GMP transfer            │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: DOE design

A statistical design matrix (definitive-screening or response-surface) is built over the process parameters — media, feed, temperature, pH, DO — across the clone or strain panel.

Stage 2: Parallel mini-bioreactor run

The matrix is executed on 24-48 disposable mini-vessels (ambr) or online-monitored microtiter plates (BioLector), each vessel under individual control with automated inoculation and feeding.

Stage 3: Online analytics and modelling

Online OD/pH/DO and automated at-line titer sampling feed a multivariate response-surface model that maps the ICH Q8 Design Space for each clone.

Stage 4: Lead selection

Clones and process conditions are ranked by titre, quality and robustness inside the Design Space, selecting the lead clone and its setpoints.

Stage 5: Scale-down validation

The lead conditions are confirmed in scale-down models that match pilot mixing, kLa and power-input so the DOE result transfers reliably.

Stage 6: GMP transfer

The characterised process and its Design Space are transferred to pilot and GMP bioreactors under FDA Process Validation Stage 1, de-risking the subsequent qualification batches.